Pfizer Snagged Another Approval for This Immunology Drug
3/1 12:30
Recently, the Food and Drug Administration (FDA) approved Pfizer's (NYSE: PFE) Xeljanz to treat adult patients with active ankylosing spondylitis who had failed to respond to at least one tumor necrosis factor (TNF) inhibitor, including AbbVie's (NYSE: ABBV) Humira. This came jus...